ADARB2 and Lewy body dementia: In synucleinopathy-associated neurodegenerative diseases, such as PD and dementia with Lewy bodies (DLB), the expression of the editing inhibitor ADAR3 is reduced by transcription inhibition due to the insolubility of NONO/SFPQ, thereby increasing the editing on many transcripts encoding axonal, synaptic and mitochondrial proteins.